Outstanding Talent, Outstanding Management
Metabolon has assembled a group of talented, experienced managers to develop and execute its business plan. We also have an impressive staff that includes specialists in biochemistry, mass spectrometry, informatics and software development.
Dr. Ryals has served as President, CEO and a member of the board of directors at Metabolon since April 2002. Prior to founding Metabolon, he was Chief Executive Officer, President and founder of Paradigm Genetics, Inc., a publicly traded agricultural biotechnology company focused on industrializing the process of gene function discovery. Dr. Ryals has 30 years of experience in the biotechnology industry, including senior research positions at Novartis and Ciba-Geigy. He currently serves on the board of directors at AgBiome, a provider of early-stage R&D for agriculture, and the advisory board of the College of Agriculture and Life Sciences at North Carolina State University. He earned a B.A. in biology and chemistry from the University of North Texas and M.S. and Ph.D. degrees in molecular biology from the University of Texas at Dallas.
Dr. Milburn has served as Chief Scientific Officer since 2005 and is responsible for global metabolomics technology development, laboratory operations, informatics, and data science. Before joining Metabolon, he was Senior Vice President of Research and Corporate Development at Sirtris Pharmaceuticals, where he led the preclinical/clinical development of drugs in metabolic disease and neurodegeneration. Prior to Sirtris, Dr. Milburn was Senior Vice President of Research at Plexxikon and was responsible for the development of its proprietary high-throughput, scaffold-based chemical technology platform. He also held various research positions at Glaxo and GlaxoWellcome from 1991 to 2001. Dr. Milburn received his Ph.D. in biophysical chemistry from the University of California, Berkeley and was a post-doctoral research fellow at Harvard Medical School.
Dr. Memel joined Metabolon in 2017 as Chief Medical Officer and is responsible for providing medical leadership in developing and delivering the company’s Precision Medicine products. He has over 25 years of leadership, innovation and operating experience in multinational pharmaceutical, diagnostics, provider and payer organizations. Prior to joining Metabolon, Dr. Memel was the Managing Director of Klaipeda Health, a healthcare and life sciences advisory company. Before Klaipeda Health, he held a variety of commercial, medical, scientific, informatics and technology leadership positions at Boehringer Ingelheim Pharmaceuticals, Aetna, Roche Diagnostics, Roche Pharmaceuticals and PeaceHealth. Dr. Memel began his career as a diagnostic and interventional radiologist. He received his B.S. and M.D. from the University of California at Los Angeles, an M.S. in medical informatics from the University of Utah, and a dual M.B.A. from Cornell University and Queen’s University in Canada. Dr. Memel also completed a Fellowship in clinical effectiveness research at the Harvard School of Public Health.
Mr. Fee joined Metabolon in 2011 and was promoted to the position of Chief Financial Officer in 2016. He has 17 years’ experience working with high-growth life sciences and technology companies and is responsible for overseeing all activities and relationships related to the financing, planning, reporting and treasury functions of the company. Prior to Metabolon, he was in the Life Sciences practice of Ernst & Young, serving both public and private life sciences companies ranging from development-stage to global organizations, guiding many through initial public offerings, public equity and debt transactions, and mergers and acquisitions. Mr. Fee is a graduate of North Carolina State University and a Certified Public Accountant.
Mr. Pettit is a human resources executive with proven abilities as a change agent building high-performance organizations and developing management teams. He has in-depth expertise in strategic human resources planning, organization development and talent acquisition and management. After graduating from Amherst College, he began his career with the Bristol Myers Company, where he held progressively more senior roles during an 11-year tenure. He then served as Senior Vice President of Human Resources & Administration for Pharmacia (now Pfizer) supporting the Americas. He moved into the biotechnology industry in 1996, accepting responsibility as Senior Vice President of Human Resources for Ligand Pharmaceuticals. Most recently, he served as Vice President of Human Resources & Administration for Intrexon Corporation.
Mr. Tolley joined Metabolon in 2015 and has responsibility for its metabolomics and biomarker services business. He is an experienced healthcare executive with a history of exceeding financial targets and a passion for improving lives. He has held a wide variety of general management, sales, marketing and business development leadership positions supporting both the lab services and medical device industries. Prior to joining Metabolon, Mr. Tolley was COO for Medikidz, a VC-backed start-up providing medical education for young people. He has also served as Vice President of Business Operations for BioAgilytix Labs and marketing director for Roche Tissue Diagnostics. Prior to joining Roche, he served as an officer in the U.S. Navy. He is a graduate of the U.S. Naval Academy (B.S., economics) and holds an M.B.A. from Harvard Business School.
Vice President, Population Health
Mr. Forrest-Hay joined Metabolon in 2017 to lead its Population Health business. He was most recently Director of Business Development at Thermo Fisher Scientific focusing on precision medicine and immuno-oncology. Mr. Forrest-Hay worked for Affymetrix for nine years prior to its 2016 acquisition by Thermo and was instrumental in closing multi-million dollar deals with the Million Veterans Program and UK Biobank. These precision medicine initiatives are the largest in the world and have analyzed DNA from over one million individuals. While at Affymetrix, he also developed and launched clinical RNA biomarker assays to enable accurate diagnosis of several types of cancer. Prior to that, Mr. Forrest-Hay was a genomics specialist at Beckman Coulter and worked as a researcher at the University of Keele. He has a molecular biology BSc Honors Degree from the University of East Anglia and a Higher National Diploma in applied biology from the University of the West of England.
Ms. Fastenau joined Metabolon in 2014 and has responsibility for its strategic communications and corporate branding. She has almost 20 years of experience in corporate communications, investor relations and public affairs and has held senior-level positions in a number of industries. She has extensive experience in U.S. and global communications in the pharmaceutical and biotechnology industries from GlaxoSmithKline, Trimeris, Triangle Pharmaceuticals (now Gilead Sciences) and consulting. Prior to her corporate communications roles, she was a vice president in the corporate finance team at an investment banking firm specializing in financial institution clients. Ms. Fastenau earned a B.S. in business administration with an economics concentration from Meredith College and holds an M.B.A. from Wake Forest University. She also completed graduate-level life sciences course work in the D.D.S. program at the University of North Carolina at Chapel Hill.